1e
In Memoriam
16
19
1
49
2
2
18
1b
1d
18
79
30
1d
2 29
1d
25
30
John Q. Trojanowski
2b 7 78Department: Pathology and Laboratory Medicine
4
1
b
1d
46
Contact information
5a
4
3
3
1d
5a
Center for Neurodegenerative Disease Researh
35 University of Pennsylvania School of Medicine
1a 3600 Spruce Street
42 3rd Floor Maloney Building
Philadelphia, PA 19104-4283
26
35 University of Pennsylvania School of Medicine
1a 3600 Spruce Street
42 3rd Floor Maloney Building
Philadelphia, PA 19104-4283
2e
Office: 215-662-6399
32 Fax: 215-349-5909
32 Lab: 215-662-3292
18
85
32 Fax: 215-349-5909
32 Lab: 215-662-3292
18
Email:
TROJANOW@UPENN.EDU
12
TROJANOW@UPENN.EDU
18
Publications
23 a
3
2
29
4
b
1f
23 a
13
Education:
21 5 c
3e University of Vienna, Vienna, Austria, 1969.
21 9 B.A. 13 (German) c
3f King's College (1965-1967 & 1969-1970), 1970.
21 5 c
51 Erasmus University Rotterdam, Rotterdam, The Netherlands, 1974.
21 a Ph.D. 19 (Neuroanatomy) c
4e Tufts University Graduate School of Arts and Sciences, 1976.
21 9 M.D. c
3c Tufts University School of Medicine, 1976.
c
3
3
3
3
8b
Permanent link21 5 c
3e University of Vienna, Vienna, Austria, 1969.
21 9 B.A. 13 (German) c
3f King's College (1965-1967 & 1969-1970), 1970.
21 5 c
51 Erasmus University Rotterdam, Rotterdam, The Netherlands, 1974.
21 a Ph.D. 19 (Neuroanatomy) c
4e Tufts University Graduate School of Arts and Sciences, 1976.
21 9 M.D. c
3c Tufts University School of Medicine, 1976.
c
2 29
21
1e
1d
24
5e
a0 Neurodegenerative diseases caused by filamentous aggregates of A-beta, tau and alpha-synuclein as well as in vitro and animal models of these diseases.
8
1b RESEARCH TECHNIQUES
ba Morphological, genetic, molecular biological and biochemical methods are used to study samples from patients with neurodegenerative diseases as well as those from model systems.
8
18 RESEARCH SUMMARY
205 Research currently centers on molecular mechanisms of neuron dysfunction, degeneration and death in normal aging and in neurodegenerative diseases (Alzheimer's and Parkinson's disease, frontotemporal dementias with/without parkinsonism, motor neuron disease, etc.). This research uses immunological, biochemical, genetic, molecular and morphological methods to study human CNS and PNS tissue samples (postmortem or surgical), cell lines, synthetic proteins, and transgenic models of neurodegenerative diseases.
65
62
e 29
27
Description of Research Expertise
23 RESEARCH INTERESTSa0 Neurodegenerative diseases caused by filamentous aggregates of A-beta, tau and alpha-synuclein as well as in vitro and animal models of these diseases.
8
1b RESEARCH TECHNIQUES
ba Morphological, genetic, molecular biological and biochemical methods are used to study samples from patients with neurodegenerative diseases as well as those from model systems.
8
18 RESEARCH SUMMARY
205 Research currently centers on molecular mechanisms of neuron dysfunction, degeneration and death in normal aging and in neurodegenerative diseases (Alzheimer's and Parkinson's disease, frontotemporal dementias with/without parkinsonism, motor neuron disease, etc.). This research uses immunological, biochemical, genetic, molecular and morphological methods to study human CNS and PNS tissue samples (postmortem or surgical), cell lines, synthetic proteins, and transgenic models of neurodegenerative diseases.
65
Description of Clinical Expertise
a7 Morphological, genetic, molecular and biological analysis of samples from patients with neurodegenerative diseases as well as those from model systems.62
Description of Other Expertise
201 Research currently centers on molecular mechanisms of neuron dysfunction, degeneration, and death in normal aging and in neurodegenerative diseases (AD and PD, frontotemporal dementias (FTD) with and without parkinsonism, motor neuron disease, etc.). This research uses immunological, biochemical, genetic, molecular, and morphological methods to study human CNS and PNS tissue samples (postmortem or surgical), cell lines, synthetic proteins, and transgenic models of neurodegenerative diseases.e 29
23
f4 Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM; Alzheimer's Disease Neuroimaging Initiative.: Association of CSF Aβ, amyloid PET and cognition in cognitively unimpaired elderly adults. 2 2f Neurology August 2020.
12c Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM, Trojanowski JQ, Höglinger GU. 56 : Distribution patterns of tau pathology in progressive supranuclear palsy. 38 Acta Neuropathol. August 2020.
7c Cornblath EJ, Robinson JL, Irwin DJ, Lee EB, Lee VM, Trojanowski JQ, Bassett DS. 3 5d : Defining and predicting transdiagnostic categories of neurodegenerative disease. 35 Nat Biomed Eng. August 2020.
12c Ewers M, Biechele G, Suárez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, Deming Y, Piccio L, Cruchaga C, Kleinberger G, Shaw L, Trojanowski JQ, Herms J, Dichgans M; Alzheimer's Disease Neuroimaging Initiative (ADNI), Brendel M, Haass C, Franzmeier N. 76 : Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. 2 3 2b EMBO Mol Med. Online ahead of print. 21 August 2020.
a1 Dai DL, Tropea TF, Robinson JL, Suh E, Hurtig H, Weintraub D, Van Deerlin V, Lee EB, Trojanowski JQ, Chen-Plotkin AS. 9b : ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. 2 36 Acta Neuropathol August 2020.
c8 Gryc W, Roberts KA, Zabetian CP, Weintraub D, Trojanowski JQ, Quinn JF, Hiller AL, Chung KA, Poston KL, Yang L, Hu SC, Edwards KL, Montine TJ, Cholerton BA. 84 : Hallucinations and Development of Dementia in Parkinson's Disease. J Parkinsons Dis. July 2020.
170 Kling MA, Goodenowe DB, Senanayake V, MahmoudianDehkordi S, Arnold M, Massaro TJ, Baillie R, Han X, Leung YY, Saykin AJ, Nho K, Kueider-Paisley A, Tenenbaum JD, Wang LS, Shaw LM, Trojanowski JQ, Kaddurah-Daouk RF; Alzheimer's Disease Metabolomics Consortium (ADMC) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). 3 80 : Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. 2 37 Alzheimers Dement. July 2020.
9b Cousins KAQ, Irwin DJ, Wolk DA, Lee EB, Shaw LMJ, Trojanowski JQ, Da Re F, Gibbons GS, Grossman M, Phillips JS. 3 6f : ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. 3 29 Brain July 2020.
7e Gao Y, Wang T, Yu X; International FTD-Genomics Consortium (IFGC), Zhao H, Zeng P. 3 8e : Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. 2 2e Sci Rep. July 2020.
2c
7
1d
1f
Selected Publications
76 Riad A, Lengyel-Zhand Z, Zeng C, Weng CC, Lee VM, Trojanowski JQ, Mach RH. 97 : The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates. 2 36 Mol Neurobiol September 2020.f4 Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM; Alzheimer's Disease Neuroimaging Initiative.: Association of CSF Aβ, amyloid PET and cognition in cognitively unimpaired elderly adults. 2 2f Neurology August 2020.
12c Kovacs GG, Lukic MJ, Irwin DJ, Arzberger T, Respondek G, Lee EB, Coughlin D, Giese A, Grossman M, Kurz C, McMillan CT, Gelpi E, Compta Y, van Swieten JC, Laat LD, Troakes C, Al-Sarraj S, Robinson JL, Roeber S, Xie SX, Lee VM, Trojanowski JQ, Höglinger GU. 56 : Distribution patterns of tau pathology in progressive supranuclear palsy. 38 Acta Neuropathol. August 2020.
7c Cornblath EJ, Robinson JL, Irwin DJ, Lee EB, Lee VM, Trojanowski JQ, Bassett DS. 3 5d : Defining and predicting transdiagnostic categories of neurodegenerative disease. 35 Nat Biomed Eng. August 2020.
12c Ewers M, Biechele G, Suárez-Calvet M, Sacher C, Blume T, Morenas-Rodriguez E, Deming Y, Piccio L, Cruchaga C, Kleinberger G, Shaw L, Trojanowski JQ, Herms J, Dichgans M; Alzheimer's Disease Neuroimaging Initiative (ADNI), Brendel M, Haass C, Franzmeier N. 76 : Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation. 2 3 2b EMBO Mol Med. Online ahead of print. 21 August 2020.
a1 Dai DL, Tropea TF, Robinson JL, Suh E, Hurtig H, Weintraub D, Van Deerlin V, Lee EB, Trojanowski JQ, Chen-Plotkin AS. 9b : ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. 2 36 Acta Neuropathol August 2020.
c8 Gryc W, Roberts KA, Zabetian CP, Weintraub D, Trojanowski JQ, Quinn JF, Hiller AL, Chung KA, Poston KL, Yang L, Hu SC, Edwards KL, Montine TJ, Cholerton BA. 84 : Hallucinations and Development of Dementia in Parkinson's Disease. J Parkinsons Dis. July 2020.
170 Kling MA, Goodenowe DB, Senanayake V, MahmoudianDehkordi S, Arnold M, Massaro TJ, Baillie R, Han X, Leung YY, Saykin AJ, Nho K, Kueider-Paisley A, Tenenbaum JD, Wang LS, Shaw LM, Trojanowski JQ, Kaddurah-Daouk RF; Alzheimer's Disease Metabolomics Consortium (ADMC) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). 3 80 : Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. 2 37 Alzheimers Dement. July 2020.
9b Cousins KAQ, Irwin DJ, Wolk DA, Lee EB, Shaw LMJ, Trojanowski JQ, Da Re F, Gibbons GS, Grossman M, Phillips JS. 3 6f : ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. 3 29 Brain July 2020.
7e Gao Y, Wang T, Yu X; International FTD-Genomics Consortium (IFGC), Zhao H, Zeng P. 3 8e : Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. 2 2e Sci Rep. July 2020.
2c